BioMarin Pharmaceutical (MEX:BMRN) Total Long-Term Assets: MXN71,877 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
19 GF Score
Price MXN959.00
GF Value MXN1,423.00
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Total Long-Term Assets?

BioMarin Pharmaceutical MEX:BMRN 19 Total Long-Term Assets is MXN71,877 Mil as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 19/100 and a GF Value™ of MXN1,423.00 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. BioMarin Pharmaceutical's Total Long-Term Assets for the quarter that ended in Mar. 2026 was MXN71,877 Mil.

BioMarin Pharmaceutical Total Long-Term Assets Related Terms

BioMarin Pharmaceutical Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Total Long-Term Assets Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76,525.16 70,646.04 65,953.70 78,344.71 65,550.33

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75,267.81 68,745.58 68,980.15 65,550.33 71,877.37
MEX:BMRN
19GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of MXN71,877 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Total Long-Term Assets of MXN71,877 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Total Long-Term Assets too high?
BioMarin Pharmaceutical's current Total Long-Term Assets is MXN71,877 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 19/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Total Long-Term Assets compare to TECH and CYTK?
BioMarin Pharmaceutical's Total Long-Term Assets of MXN71,877 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Total Long-Term Assets is MXN71,877 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,423.00, compared to a current price of MXN959.00 — trading 32.6% below its estimated fair value. The current Total Long-Term Assets is MXN71,877 Mil. BioMarin Pharmaceutical's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Total Long-Term Assets is MXN71,877 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 32.6% below its estimated GF Value™ of MXN1,423.00. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Total Long-Term Assets: MXN71,877 Mil
  • GF Value™: MXN1,423.00 vs. price of MXN959.00 (32.6% below fair value)
  • GF Score™: 19/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
19GF Score

Get the complete analysis for MEX:BMRN

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,423.00
GF Value